Pharmacologic basis for the treatment of cardiac arrhythmias

H. Gelband, M. R. Rosen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Information and experience here are often limited, and in many instances the determining factor in selection and method of administration of a drug to the pediatric patient is its use in the treatment of arrhythmias in the adult. Additional requirements for the rational choice of the proper antiarrhythmic agent are an accurate diagnosis of the cardiac arrhythmia; a knowledge of the mechanism for initiation and maintenace of an arrhythmia; an understanding of the electrophysiologic effects, pharmacologic properties and metabolism of the drugs available; and the clinical status of the patient. Any electrolyte imbalance, concomitant drug therapy or organ system dysfunction may alter the absorption and metabolism of the drug. Although the simultaneous use of combinations of arrhythmic drugs in the initial treatment of arrhythmias appears to be a common clinical practice, the authors do not recommend this. When more than one drug is administered it is difficult to determine which is responsible for a therapeutic effect, and equally important which is responsible for undesirable effects should they occur. Hence, it is preferable to employ single drug therapy with frequent clinical evaluations and determinations of plasma concentrations as a guide in the management of the arrhythmia. Since sparse information is available concerning the pharmacokinetics of antiarrhythmic drugs in pediatric patients, the pediatric patient may require higher doses of a specific drug on a per kilogram basis to control his arrhythmia than would be required by an adult, as evidenced by the use of procaineamide and digitalis. When therapeutic doses or plasma concentrations of antiarrhythmic drugs fail to produce a desired antiarrhythmic effect, the drug should be continued to be administered cautiously in increasing amounts until minimal toxic manifestations occur or the arrhythmia is terminated. In instances where a specific single drug fails, another antiarrhythmic agent should be resorted to. Combined drug therapy should be utilized only when the use of single agents fails.

Original languageEnglish
Pages (from-to)59-67
Number of pages9
JournalPediatrics
Volume55
Issue number1
StatePublished - Dec 1 1975
Externally publishedYes

Fingerprint

Cardiac Arrhythmias
Anti-Arrhythmia Agents
Pharmaceutical Preparations
Pediatrics
Drug Therapy
Therapeutics
Digitalis
Poisons
Therapeutic Uses
Drug Combinations
Electrolytes
Pharmacokinetics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Gelband, H., & Rosen, M. R. (1975). Pharmacologic basis for the treatment of cardiac arrhythmias. Pediatrics, 55(1), 59-67.

Pharmacologic basis for the treatment of cardiac arrhythmias. / Gelband, H.; Rosen, M. R.

In: Pediatrics, Vol. 55, No. 1, 01.12.1975, p. 59-67.

Research output: Contribution to journalArticle

Gelband, H & Rosen, MR 1975, 'Pharmacologic basis for the treatment of cardiac arrhythmias', Pediatrics, vol. 55, no. 1, pp. 59-67.
Gelband H, Rosen MR. Pharmacologic basis for the treatment of cardiac arrhythmias. Pediatrics. 1975 Dec 1;55(1):59-67.
Gelband, H. ; Rosen, M. R. / Pharmacologic basis for the treatment of cardiac arrhythmias. In: Pediatrics. 1975 ; Vol. 55, No. 1. pp. 59-67.
@article{d740167fe8f4420e8b055d95cf0b16c5,
title = "Pharmacologic basis for the treatment of cardiac arrhythmias",
abstract = "Information and experience here are often limited, and in many instances the determining factor in selection and method of administration of a drug to the pediatric patient is its use in the treatment of arrhythmias in the adult. Additional requirements for the rational choice of the proper antiarrhythmic agent are an accurate diagnosis of the cardiac arrhythmia; a knowledge of the mechanism for initiation and maintenace of an arrhythmia; an understanding of the electrophysiologic effects, pharmacologic properties and metabolism of the drugs available; and the clinical status of the patient. Any electrolyte imbalance, concomitant drug therapy or organ system dysfunction may alter the absorption and metabolism of the drug. Although the simultaneous use of combinations of arrhythmic drugs in the initial treatment of arrhythmias appears to be a common clinical practice, the authors do not recommend this. When more than one drug is administered it is difficult to determine which is responsible for a therapeutic effect, and equally important which is responsible for undesirable effects should they occur. Hence, it is preferable to employ single drug therapy with frequent clinical evaluations and determinations of plasma concentrations as a guide in the management of the arrhythmia. Since sparse information is available concerning the pharmacokinetics of antiarrhythmic drugs in pediatric patients, the pediatric patient may require higher doses of a specific drug on a per kilogram basis to control his arrhythmia than would be required by an adult, as evidenced by the use of procaineamide and digitalis. When therapeutic doses or plasma concentrations of antiarrhythmic drugs fail to produce a desired antiarrhythmic effect, the drug should be continued to be administered cautiously in increasing amounts until minimal toxic manifestations occur or the arrhythmia is terminated. In instances where a specific single drug fails, another antiarrhythmic agent should be resorted to. Combined drug therapy should be utilized only when the use of single agents fails.",
author = "H. Gelband and Rosen, {M. R.}",
year = "1975",
month = "12",
day = "1",
language = "English",
volume = "55",
pages = "59--67",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "1",

}

TY - JOUR

T1 - Pharmacologic basis for the treatment of cardiac arrhythmias

AU - Gelband, H.

AU - Rosen, M. R.

PY - 1975/12/1

Y1 - 1975/12/1

N2 - Information and experience here are often limited, and in many instances the determining factor in selection and method of administration of a drug to the pediatric patient is its use in the treatment of arrhythmias in the adult. Additional requirements for the rational choice of the proper antiarrhythmic agent are an accurate diagnosis of the cardiac arrhythmia; a knowledge of the mechanism for initiation and maintenace of an arrhythmia; an understanding of the electrophysiologic effects, pharmacologic properties and metabolism of the drugs available; and the clinical status of the patient. Any electrolyte imbalance, concomitant drug therapy or organ system dysfunction may alter the absorption and metabolism of the drug. Although the simultaneous use of combinations of arrhythmic drugs in the initial treatment of arrhythmias appears to be a common clinical practice, the authors do not recommend this. When more than one drug is administered it is difficult to determine which is responsible for a therapeutic effect, and equally important which is responsible for undesirable effects should they occur. Hence, it is preferable to employ single drug therapy with frequent clinical evaluations and determinations of plasma concentrations as a guide in the management of the arrhythmia. Since sparse information is available concerning the pharmacokinetics of antiarrhythmic drugs in pediatric patients, the pediatric patient may require higher doses of a specific drug on a per kilogram basis to control his arrhythmia than would be required by an adult, as evidenced by the use of procaineamide and digitalis. When therapeutic doses or plasma concentrations of antiarrhythmic drugs fail to produce a desired antiarrhythmic effect, the drug should be continued to be administered cautiously in increasing amounts until minimal toxic manifestations occur or the arrhythmia is terminated. In instances where a specific single drug fails, another antiarrhythmic agent should be resorted to. Combined drug therapy should be utilized only when the use of single agents fails.

AB - Information and experience here are often limited, and in many instances the determining factor in selection and method of administration of a drug to the pediatric patient is its use in the treatment of arrhythmias in the adult. Additional requirements for the rational choice of the proper antiarrhythmic agent are an accurate diagnosis of the cardiac arrhythmia; a knowledge of the mechanism for initiation and maintenace of an arrhythmia; an understanding of the electrophysiologic effects, pharmacologic properties and metabolism of the drugs available; and the clinical status of the patient. Any electrolyte imbalance, concomitant drug therapy or organ system dysfunction may alter the absorption and metabolism of the drug. Although the simultaneous use of combinations of arrhythmic drugs in the initial treatment of arrhythmias appears to be a common clinical practice, the authors do not recommend this. When more than one drug is administered it is difficult to determine which is responsible for a therapeutic effect, and equally important which is responsible for undesirable effects should they occur. Hence, it is preferable to employ single drug therapy with frequent clinical evaluations and determinations of plasma concentrations as a guide in the management of the arrhythmia. Since sparse information is available concerning the pharmacokinetics of antiarrhythmic drugs in pediatric patients, the pediatric patient may require higher doses of a specific drug on a per kilogram basis to control his arrhythmia than would be required by an adult, as evidenced by the use of procaineamide and digitalis. When therapeutic doses or plasma concentrations of antiarrhythmic drugs fail to produce a desired antiarrhythmic effect, the drug should be continued to be administered cautiously in increasing amounts until minimal toxic manifestations occur or the arrhythmia is terminated. In instances where a specific single drug fails, another antiarrhythmic agent should be resorted to. Combined drug therapy should be utilized only when the use of single agents fails.

UR - http://www.scopus.com/inward/record.url?scp=0016639583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016639583&partnerID=8YFLogxK

M3 - Article

C2 - 1089243

AN - SCOPUS:0016639583

VL - 55

SP - 59

EP - 67

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 1

ER -